In many cases, only wealthy people will be able to get their hands on obesity treatments, even though the disease disproportionately affects people with lower incomes
Clinical Evidence and Expectations The STEP trials, which evaluated the efficacy of semaglutide, demonstrated that weight loss and appetite suppression are dose-dependent
Gastrointestinal symptoms are the most common manifestations of tirzepatide overdose and may include: Severe nausea and vomiting : Often persistent and more intense than typical side effects, potentially leading to inability to retain fluids or medications Abdominal pain or cramping : May range from mild discomfort to severe pain, typically in the upper abdomen Diarrhea : Can contribute to dehydration and electrolyte imbalances Loss of appetite : Complete aversion to food, extending beyond normal appetite suppression Metabolic disturbances requiring medical attention: Hypoglycemia : Symptoms include trembling, sweating, rapid heartbeat, confusion, dizziness, hunger, irritability, and in severe cases, loss of consciousness or seizures
These characteristics make GLP-1RAs important treatment options for type 2 diabetes and obesity
differentiation phenotype, they may be acting redundantly in regulating this process